Evaluation of the Biological Effects of Lyophilized Hydrophilic Extract of Rhus coriaria on Myeloperoxidase (MPO) Activity, Wound Healing, and Microbial Infections of Skin Wound Tissues

Table 1

Full elucidation of experimental design.

Group	Description
G1:	Saline non infected group; rats received topical application (200 μL) of solutions containing saline (NaCl, 0.9%).
G2:	Standard treatment group; non-infected rats received fibrinolysin (Fibrase SA®) topically as once daily at a dose of 0.5 g.
G3:	Non infected Rats treated with AERc extract at doses of 5 mg.kg-1 for once a day for 9 consecutive days starting from the day of wounding.
G4:	Non-infected Rats treated with AERc extract at doses of 10nmg.kg-1 for once a day for 9 consecutive days starting from the day of wounding.
G5:	Saline infected group; infected rats with either Staphylococcus aureus (ATCC 25923) or Pseudomonas aeruginosa received topical application (200 μL) of solutions containing saline (NaCl, 0.9%).
G6:	Infected rats with either Staphylococcus aureus (ATCC 25923) or Pseudomonas aeruginosa received 1% silver sulfadiazine (Dermazine®) topically as standard treatment once daily
G7:	Infected rats with Staphylococcus aureus (ATCC 25923) treated with AERc extract at doses of 5 mg.kg-1 for once a day for 9 consecutive days starting from the day of wounding
G8:	Infected rats with Staphylococcus aureus (ATCC 25923) treated with AERc extract at doses of 10 mg.kg-1 for once a day for 9 consecutive days starting from the day of wounding
G9:	Infected rats with Pseudomonas aeruginosa received AERc extract at doses of 5 mg.kg-1 for once a day for 9 consecutive days starting from the day of wounding
G10:	Infected rats with Pseudomonas aeruginosa received AERc extract at doses of 10 mg.kg-1 for once a day for 9 consecutive days starting from the day of wounding